Case Report
Copyright ©The Author(s) 2020.
World J Gastrointest Oncol. Dec 15, 2020; 12(12): 1456-1463
Published online Dec 15, 2020. doi: 10.4251/wjgo.v12.i12.1456
Figure 4
Figure 4 18F-fluoro-D-glucose positron emission tomography/X-ray computed tomography performed after three months of maintenance olaparib. A and B: 18F-fluoro-D-glucose positron emission tomography/X-ray computed tomography shows complete metabolic normalization of the pancreatic lesion, which is also reduced in size.

  • Citation: Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R. Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World J Gastrointest Oncol 2020; 12(12): 1456-1463
  • URL: https://www.wjgnet.com/1948-5204/full/v12/i12/1456.htm
  • DOI: https://dx.doi.org/10.4251/wjgo.v12.i12.1456